Gipsies and drug addictions. Study of the adherence to treatment

European Addiction Research

Volumn 6, Issue 1, 2000, Pages 34-41

  Iraurgi, I ^a   Jimenez Lerma J M ^b   Landabaso, M A ^b   Arrazola, X ^b   Gutierrez Fraile M ^b  

^a Modulo Asistencia Psicosocial R   (Spain)

^b NONE

Author keywords

Adherence to treatment; Ethnical groups; Gipsy; Heroin addiction; Naltrexone programme; Retention rates

Indexed keywords

NALTREXONE; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CULTURAL FACTOR; DRUG DEPENDENCE; ETHNIC GROUP; FEMALE; GIPSY; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; SPAIN; SURVIVAL; COMPARATIVE STUDY; FOLLOW UP; HEROIN DEPENDENCE; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; RETROSPECTIVE STUDY;

ADULT; COHORT STUDIES; CROSS-CULTURAL COMPARISON; FEMALE; FOLLOW-UP STUDIES; GYPSIES; HEROIN DEPENDENCE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; SPAIN;

EID: 0033624899     PISSN: 10226877     EISSN: None     Source Type: Journal    
DOI: 10.1159/000019007     Document Type: Article

References (46)

1. Kosten TA, Kosten TR: Pharmacological blocking agents for treating substance abuse. J Nerv Ment Dis 1991;10:583-592.
2. González JP, Brogden RM: Naltrexone: A review. Drugs 1988;35:192-213.
3. Goldstein A: Adicción (Addiction). Barcelona, Ediciones en Neurociencias, 1995.
4. Judson BA, Goldstein A: Naltrexone treatment of heroin addiction: One-year follow-up. Drug Alcohol Dep 1984;13:357-365.
5. Kosten TR, Rounsaville BJ, Kleber HD: Predictors of 2.5 year outcome in opioid addicts: Pretreatment source of income. Am J Drug Alcohol Abuse 1987;13:19-32.
6. Pinet MC, Terradas A, Trujols J: Aspectos metodológicos de los programas de mantenimiento con naltrexona (Methodological aspects of the naltrexone maintenance programs): in Casas M, Gutièrrez M, San L (eds): Avances en drogodependencias (Advances in Drug Addiction). Barcelona, Ediciones en Neurociencias, 1994, pp 109-128.
7. Iraurgi I, Jiménez-Lerma JM, Herrera A, Murua F, Landabaso MA, Gutiérrez-Fraile M: Analysis of the adherence predictors for an opiate antagonist programme. Itaca 1998;1: 43-00.
8. Hollister I.E. Boarman JE, Duster TS: Clinical evaluation of naltrexone treatment of opiate-dependent individual. Arch Gen Psychiatry 1978;35:335-340.
9. Resnick RB, Washton AM: Clinical outcome with naltrexone: Recent Developments in Chemotherapy Narcotic Addiction. Ann NY Acad Sci 1978;311:241-247.
10. Renault PF: Treatment of heroin-dependent persons with antagonists: current status; in Willete RE, Barnet G (eds): Naltrexone. Washington, NIDA Research Monograph 28, 1980, pp 11-22.
11. Resnick RH, Washton AM, Stone-Washton N: Psychotherapy and naltrexone in opioid dependence; in Harris LS (ed): Problems of Drug Dependence, Rockville, NIDA Research Monograph 34, 1981, pp 109-115.
12. Greenstein RA, Evans BD, McLellan AT, O'Brien CP: Predictors of favorable outcome following naltrexone treatment. Drug Alcohol Depend. 1983;12:173-180.
13. Ling W, Wesson DR: Naltrexone treatment for addicts health-care professionals: A collaborative private practice experience. J Clin Psychiatry 1984;45:46-48.
14. Washton AM, Pottash S, Gold MS: Naltrexone in addicted business executives and physicians. J Clin Psychiatry 1984;45:39-41.
15. Kleber HD: Naltrexone. J Subst Abuse Treat 1985;2:117-122.
16. Herridge P, Gold MS: Pharmacological adjuncts in the treatment of opioid and cocaine addicts. J Psychoactive Drugs 1988;20:233-242.
17. Forteza-Rei J, Mestre L, Serra J, Gallo J, Altés J: Nuestra experiencia en 100 tratamientos con naltrexona (Our experience in 100 addicts treated with naltrexone). Adicciones 1989;1: 83-95.
18. Ochoa E, Cebollada AS, Ibáñez A: Implicación familiar como predictor en un tratamiento de mantenimiento con antagonistas opiáceos (Family involvement as a way to predict a maintenance treatment with antagonism opiates). Adicciones 1994;6:51-60.
19. Arias F, López-Ibor JJ, Ochoa E: Predictores evolutivos en un programa de mantenimiento con naltrexona (Evolutive predictors in a naltrexone maintenance programme). Adicciones 1996;8:479-500.
20. Tennant FS, Rawon RA, Cohen AJ, Mann A: Clinical experience with naltrexone in suburban opioid addicts. J Clin Psychiatry 1984;45: 42-45.
21. Sánchez-Carbonell J, Camí J, Brigos B: Follow-up of heroin addicts in Spain (EMETYST Project): Results 1 year after treatment admission. Br J Addiction 1988;83:1439-1448.
22. García-Alonso F, Gutiérrez M, San L, Bedate J, Forteza-Rei J, Rodríguez-Artalejo F, Palop R, Lópev-Álvarez M, Péred-de-los-Cobos JC, Cami J and the Spainsh Study Group in Drug Addiction: A multicenter study to introduce naltrexona for opiate dependence in Spain. Drug Alcohol Depend 1989;23:117-121.
23. García A, Ezquiaga E: Estudio de una muestra de 433 drogodependientes que acudieron a un centro de salud mental (Description of 433 drug addicts attended in a mental health centre). Adicciones 1991;3:167-180.
24. Ochoa E, Arias F, Somoza JC, Vicente N, Jordá L: Retención en un programa de tratamiento con naltrexona: Dos años de seguimiento (Retention in a naltrexone programme treatment: Two years follow-up). Adicciones 1992;4:207-212.
25. Ochoa E, Arias F, Ciudad A, Martín NJ: Deshabituación con naltrexona en la dependencia a opiáccos: Un estudio evolutivo (treatment with naltrexone in opiate dependence: a follow-up study). Rev Esp Drogodep 1993;18:233-246.
26. Bedate J, Bobes J, Ochoa E, Sole J: Eval̇uación del tratamiento de los heroinómanos con naltrexona. Estudio multicéntrico (Evaluation of the treatment of heroin-addicts with naltrexone, multi-centre study); in Casas M, Gutiérrez M, San L (eds): Avances en drogodependencias (Advances in Drug Addictions). Barcelona, Ediciones en Neurociencias, 1994, pp 129-168.
27. Iraurgi I, Jiménez-Lerma JM, Herrera A, Murua F, Gutiérrez-Fraile M: Tasas de retención y consumo en un programa de antagonistas opiáccos. Un análisis de supervivencia (Retention and lapse rates within an opiate antagonist programme. A survival analysis). Adicciones 1997; 9:7-21.
28. Gamella JF: La población gitana en Andalucía (The gipsy community in Andalucia). Junta de Andalucía, Consejería de Trabajo y Asuntos Sociales, 1996.
29. Asociación Gitana Gao Lacho Drom: Los gitanos y las toxicomanías en Alava (Gipsies and Toxicomanies in Alava). Vitoria-Gasteiz, Asociación Gitana Gao Lacho Drom, in press.
30. Rodríguez I: La comunidad gitana española y la intervención en drogodependencias (The spanish gipsy community and the drogodependence). Madrid, Jornadas Europeas sobre Drogas y Comunidad Gitana, 1996.
31. Grupo PASS: Gitanos y Drogas (Gipsies and Drugs). Madrid, Secretariado General Gitano, Serie cuadernos técnicos N° 10, 1987.
32. Osakidetza: Mcmoria del Hospital Psiquiátrico de Alava 1994 (Psychiatric Hospital of Alava, 1994 Report). Vitoria, Asistencia Psiquiátrica y Salud Mental Extrahospitalaria de Alava, 1995.
33. Barrutia I: Development of a group for treating drug addiction amongst gipsies. Itaca 1998;1: 7-30.
34. Jiménez-Lerma JM, Iraurgi I, Zubizarreta I, Murua F, Herrera A, Landabaso MA, Gutiérrez-Fraile M: Caracteristicas sociodemográficas y niveles de retención de un programa de antagonistas opiáccos en un colectivo gitano (Sociobiographical characteristics and retention rates of an opiate antagonist programme in gipsy collective). Adicciones 1998;10:24-31.
35. APA: DSM-III-R. Manual Diagnóstico y Estadístico de los Trastornos Mentales (Diagnostic and Statistical Manual of Mental Disorders). Barcelona. Masson, 1988.
36. Kleber HD, Kosten TR: Naltrexone induction: Psychologic and pharmacologic strategies. J Clin Psychiatry 1984;45:29-38.
37. Haeks RL, Chiang CN: Urine Testing for Drugs of Abuse. Research Monograps 73. Maryland, Natinal Institute on Drugs Abuse, Department of Health and Human Sciences, 1986.
38. Oerellich M: Enzyme immnoassays in clinical chemistry: Present status and trends. J Clin Chem Clin Biochem 1980;18:197-208.
39. Harris EK, Albert A: Survivorship Analysis for Clinical Studies. New York, Marcel Dekker, 1991.
40. Norusis MJ: Statistical Package for the Social Sciences. Release 6.1. Chicago, SPSS Inc. 1994.
41. Cheung YW: Approaches to ethnicity: Clearing roadblocks in the study of ethnicity and substance use. Int J Addict 1993;28:1209-1226.
42. Moore D: Ethnography and illicit drug use: Dispatches from an anthropologist in the field. Addiction Res 1993;1:11-25.
43. Kline A: Pathways into drug user treatment: The influence of gender an racial-ethnic identity. Substance Use Misuse 1996;31:323-342.
44. Delegación del Gobierno para el Plan Nacional sobre Drogas: Sistema Estatal de Información sobre Toxicomanías. Informe 1995 (State Information System on Drug Abuse. 1995 Report). Madrid, Ministerio del Interior, 1996.
45. UNISAT: Unión Nationale de Insittutions Sociales d'Actions pour les tsiganes: Los gitanos y la drogodependencia en Francia (The gipsies and the drug addiction in France). Madrid, Jornadas Europeas sobre Drogas y Comunidad Gitana, 1996.
46. San Román T: Vecinos gitanos (Gipsy neighbour). Madrid, Akal, 1976.